Psychopharmacology :: a mental health professional's guide to commonly used medications /
An updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes.
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
St. Albans:
Critical Publishing,
2021.
|
| Ausgabe: | Second edition |
| Schriftenreihe: | Nursing.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | An updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes. |
| Beschreibung: | 1 online resource (xiii, 314 pages) |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781914171451 1914171454 9781914171468 1914171462 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1268332849 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 210917s2021 enk o 000 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d EBLCP |d OCLCO |d OCLCF |d YT1 |d OCLCO |d OCLCQ |d OCLCO |d OCLCL |d UKOBU |d UKMGB |d UKAHL |d ZCI |d YDX | ||
| 015 | |a GBC1A7890 |2 bnb | ||
| 016 | 7 | |a 020250869 |2 Uk | |
| 019 | |a 1267686652 |a 1267760905 |a 1277060219 |a 1285703671 |a 1302880703 | ||
| 020 | |a 9781914171451 |q (electronic bk.) | ||
| 020 | |a 1914171454 |q (electronic bk.) | ||
| 020 | |z 9781914171444 | ||
| 020 | |a 9781914171468 |q (PDF ebook) | ||
| 020 | |a 1914171462 | ||
| 020 | |z 1914171446 | ||
| 035 | |a (OCoLC)1268332849 |z (OCoLC)1267686652 |z (OCoLC)1267760905 |z (OCoLC)1277060219 |z (OCoLC)1285703671 |z (OCoLC)1302880703 | ||
| 037 | |a 3-149-9781914171451 |b Ingram Content Group | ||
| 050 | 4 | |a RM315 | |
| 060 | 4 | |a QV 77.2 |b M994 2021 | |
| 082 | 7 | |a 615.78 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Mwebe, Herbert, |e author |1 https://id.oclc.org/worldcat/entity/E39PCjKPbVpc9tYvyPVFMFRc4C |0 http://id.loc.gov/authorities/names/n2018189905 | |
| 245 | 1 | 0 | |a Psychopharmacology : |b a mental health professional's guide to commonly used medications / |c Herbert Mwebe. |
| 250 | |a Second edition | ||
| 264 | 1 | |a St. Albans: |b Critical Publishing, |c 2021. | |
| 300 | |a 1 online resource (xiii, 314 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Nursing | |
| 588 | 0 | |a Vendor-supplied metadata. | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Cover -- Title page -- Copyright information -- Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia | |
| 505 | 8 | |a 2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia | |
| 505 | 8 | |a Management of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy | |
| 505 | 8 | |a Clozapine alert -- Other adverse effects of clozapine -- Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK®3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations | |
| 505 | 8 | |a Key points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion) | |
| 520 | |a An updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes. | ||
| 650 | 0 | |a Psychopharmacology |v Handbooks, manuals, etc. | |
| 650 | 6 | |a Psychopharmacologie |v Guides, manuels, etc. | |
| 650 | 7 | |a Psychopharmacology |2 fast | |
| 650 | 2 | |a Psychopharmacology |0 https://id.nlm.nih.gov/mesh/D011600 | |
| 655 | 7 | |a Handbooks and manuals |2 fast | |
| 758 | |i has work: |a PSYCHOPHARMACOLOGY (Text) |1 https://id.oclc.org/worldcat/entity/E39PD39fdC4h3p3wx6dD8GcPry |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Mwebe, Herbert |t Psychopharmacology |d St Albans : Critical Publishing,c2021 |z 9781914171444 |
| 830 | 0 | |a Nursing. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3028130 |3 Volltext |
| 938 | |a EBSCOhost |b EBSC |n 3028130 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6720711 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH38936614 | ||
| 938 | |a YBP Library Services |b YANK |n 302450461 | ||
| 938 | |a YBP Library Services |b YANK |n 17630715 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1268332849 |
|---|---|
| _version_ | 1816882550154461185 |
| adam_text | |
| any_adam_object | |
| author | Mwebe, Herbert |
| author_GND | http://id.loc.gov/authorities/names/n2018189905 |
| author_facet | Mwebe, Herbert |
| author_role | aut |
| author_sort | Mwebe, Herbert |
| author_variant | h m hm |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM315 |
| callnumber-raw | RM315 |
| callnumber-search | RM315 |
| callnumber-sort | RM 3315 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Cover -- Title page -- Copyright information -- Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia 2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia Management of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy Clozapine alert -- Other adverse effects of clozapine -- Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK®3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations Key points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion) |
| ctrlnum | (OCoLC)1268332849 |
| dewey-full | 615.78 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.78 |
| dewey-search | 615.78 |
| dewey-sort | 3615.78 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | Second edition |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05968cam a2200673 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1268332849</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu|||unuuu</controlfield><controlfield tag="008">210917s2021 enk o 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCF</subfield><subfield code="d">YT1</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">UKOBU</subfield><subfield code="d">UKMGB</subfield><subfield code="d">UKAHL</subfield><subfield code="d">ZCI</subfield><subfield code="d">YDX</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBC1A7890</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">020250869</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1267686652</subfield><subfield code="a">1267760905</subfield><subfield code="a">1277060219</subfield><subfield code="a">1285703671</subfield><subfield code="a">1302880703</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781914171451</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1914171454</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781914171444</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781914171468</subfield><subfield code="q">(PDF ebook)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1914171462</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1914171446</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1268332849</subfield><subfield code="z">(OCoLC)1267686652</subfield><subfield code="z">(OCoLC)1267760905</subfield><subfield code="z">(OCoLC)1277060219</subfield><subfield code="z">(OCoLC)1285703671</subfield><subfield code="z">(OCoLC)1302880703</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">3-149-9781914171451</subfield><subfield code="b">Ingram Content Group</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM315</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 77.2</subfield><subfield code="b">M994 2021</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.78</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mwebe, Herbert,</subfield><subfield code="e">author</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCjKPbVpc9tYvyPVFMFRc4C</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2018189905</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Psychopharmacology :</subfield><subfield code="b">a mental health professional's guide to commonly used medications /</subfield><subfield code="c">Herbert Mwebe.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Second edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">St. Albans:</subfield><subfield code="b">Critical Publishing,</subfield><subfield code="c">2021.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xiii, 314 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Nursing</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Vendor-supplied metadata.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover -- Title page -- Copyright information -- Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Management of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Clozapine alert -- Other adverse effects of clozapine -- Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK®3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Key points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">An updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Psychopharmacology</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Psychopharmacologie</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Psychopharmacology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Psychopharmacology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D011600</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Handbooks and manuals</subfield><subfield code="2">fast</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">PSYCHOPHARMACOLOGY (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PD39fdC4h3p3wx6dD8GcPry</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Mwebe, Herbert</subfield><subfield code="t">Psychopharmacology</subfield><subfield code="d">St Albans : Critical Publishing,c2021</subfield><subfield code="z">9781914171444</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Nursing.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3028130</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">3028130</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL6720711</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH38936614</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">302450461</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">17630715</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Handbooks and manuals fast |
| genre_facet | Handbooks and manuals |
| id | ZDB-4-EBA-on1268332849 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:23Z |
| institution | BVB |
| isbn | 9781914171451 1914171454 9781914171468 1914171462 |
| language | English |
| oclc_num | 1268332849 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xiii, 314 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2021 |
| publishDateSearch | 2021 |
| publishDateSort | 2021 |
| publisher | Critical Publishing, |
| record_format | marc |
| series | Nursing. |
| series2 | Nursing |
| spelling | Mwebe, Herbert, author https://id.oclc.org/worldcat/entity/E39PCjKPbVpc9tYvyPVFMFRc4C http://id.loc.gov/authorities/names/n2018189905 Psychopharmacology : a mental health professional's guide to commonly used medications / Herbert Mwebe. Second edition St. Albans: Critical Publishing, 2021. 1 online resource (xiii, 314 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Nursing Vendor-supplied metadata. Includes bibliographical references and index. Cover -- Title page -- Copyright information -- Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia 2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia Management of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy Clozapine alert -- Other adverse effects of clozapine -- Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK®3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations Key points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion) An updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes. Psychopharmacology Handbooks, manuals, etc. Psychopharmacologie Guides, manuels, etc. Psychopharmacology fast Psychopharmacology https://id.nlm.nih.gov/mesh/D011600 Handbooks and manuals fast has work: PSYCHOPHARMACOLOGY (Text) https://id.oclc.org/worldcat/entity/E39PD39fdC4h3p3wx6dD8GcPry https://id.oclc.org/worldcat/ontology/hasWork Print version: Mwebe, Herbert Psychopharmacology St Albans : Critical Publishing,c2021 9781914171444 Nursing. FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3028130 Volltext |
| spellingShingle | Mwebe, Herbert Psychopharmacology : a mental health professional's guide to commonly used medications / Nursing. Cover -- Title page -- Copyright information -- Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia 2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia Management of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy Clozapine alert -- Other adverse effects of clozapine -- Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK®3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations Key points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion) Psychopharmacology Handbooks, manuals, etc. Psychopharmacologie Guides, manuels, etc. Psychopharmacology fast Psychopharmacology https://id.nlm.nih.gov/mesh/D011600 |
| subject_GND | https://id.nlm.nih.gov/mesh/D011600 |
| title | Psychopharmacology : a mental health professional's guide to commonly used medications / |
| title_auth | Psychopharmacology : a mental health professional's guide to commonly used medications / |
| title_exact_search | Psychopharmacology : a mental health professional's guide to commonly used medications / |
| title_full | Psychopharmacology : a mental health professional's guide to commonly used medications / Herbert Mwebe. |
| title_fullStr | Psychopharmacology : a mental health professional's guide to commonly used medications / Herbert Mwebe. |
| title_full_unstemmed | Psychopharmacology : a mental health professional's guide to commonly used medications / Herbert Mwebe. |
| title_short | Psychopharmacology : |
| title_sort | psychopharmacology a mental health professional s guide to commonly used medications |
| title_sub | a mental health professional's guide to commonly used medications / |
| topic | Psychopharmacology Handbooks, manuals, etc. Psychopharmacologie Guides, manuels, etc. Psychopharmacology fast Psychopharmacology https://id.nlm.nih.gov/mesh/D011600 |
| topic_facet | Psychopharmacology Handbooks, manuals, etc. Psychopharmacologie Guides, manuels, etc. Psychopharmacology Handbooks and manuals |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3028130 |
| work_keys_str_mv | AT mwebeherbert psychopharmacologyamentalhealthprofessionalsguidetocommonlyusedmedications |